Tat-Beclin-1 Dosing Calculator
Tat-Beclin-1: cell-permeable autophagy-inducing peptide from beclin 1/HIV Tat.
Pre-filled with the most-reported community reconstitution protocol for Tat-Beclin-1. See how 1 mL and 2 mL of bacteriostatic water change concentration and syringe-draw volume, then adjust the calculator below for your own vial.
Quick answer · Community-reported standard
A 5 mg vial of Tat-Beclin-1 reconstituted with 1 mL of bacteriostatic water yields a concentration of 2.50 mg/mL. At that concentration, a 100 mcg dose of Tat-Beclin-1 equals 4 units on a U-100 insulin syringe (0.040 mL). Tat-Beclin-1 is typically administered every other day via subcutaneous.
Tat-Beclin-1 reconstitution: 1 mL vs 2 mL bac water
Bacteriostatic water volume is flexible. Less water means higher concentration and smaller injection volumes; more water means lower concentration and easier dose precision. Both options below are valid for a 5 mg vial.
| BAC water added | Concentration | Volume per 100 mcg dose | Draw on U-100 syringe (units) |
|---|---|---|---|
| 1 mL | 5.00 mg/mL | 0.020 mL | 2 units |
| 2 mL | 2.50 mg/mL | 0.040 mL | 4 units |
Calculate your Tat-Beclin-1 dose
Alternative Tat-Beclin-1 protocols
Beyond the default above, Tat-Beclin-1 is also reported in the following protocols. Use these as starting points and recalculate with the tool above.
In Vitro Autophagy Induction
Clinical- Dose
- Typical in vitro concentrations range from 0.5 to 50 micromolar depending on the cell type and experimental endpoint. Antiviral studies in macrophages used 0.5 to 5 micromolar for HIV-1 inhibition with dose-dependent effects. Higher concentrations (above 20-50 micromolar) may trigger autosis (autophagy-dependent cell death).
- Frequency
- Single treatment or repeated dosing during cell culture experiments
- Duration
- Varies by experimental design (hours to days)
The L-form (Tat-L11) is commonly used for in vitro experiments. Tat-Scrambled serves as the standard negative control peptide. Dose-response experiments are critical to identify the therapeutic window between autophagy induction and autosis.
In Vivo Antiviral Studies (Mouse, IP)
Clinical- Dose
- In the original Shoji-Kawata et al. (Nature 2013) study, mice received 15 mg/kg Tat-Beclin-1 via intraperitoneal injection daily beginning 1 day post-infection with West Nile virus, continuing for 20 days. This dose induced autophagy in peripheral tissues and CNS of neonatal mice.
- Frequency
- Daily intraperitoneal injection
- Duration
- 20 days in the West Nile virus survival study
The retro-inverso D-form is preferred for in vivo use due to enhanced resistance to proteolytic degradation. Mouse doses are not translatable to human dosing. No human PK data exists.
In Vivo Anticancer Studies (Mouse, IP)
Clinical- Dose
- In HER2-positive breast cancer xenograft studies (Vega-Rubin-de-Celis et al., PNAS 2018), Tat-Beclin-1 was administered daily via intraperitoneal injection when tumor volume reached 200 mm3. The peptide was as effective as the clinically approved drug lapatinib in reducing tumor progression.
- Frequency
- Daily intraperitoneal injection
- Duration
- Duration of xenograft study until tumor endpoint
Published in PNAS (2018). Mouse xenograft dosing does not predict human anticancer dosing. Specific mg/kg dose for anticancer studies should be confirmed from the primary publication.
Tat-Beclin-1 reconstitution & storage
Tat-Beclin-1 is supplied as lyophilized powder. Reconstitute in sterile water, PBS, or DMSO depending on supplier recommendations and experimental requirements. Typical stock concentration is 1-10 mM. Aliquot reconstituted peptide to avoid freeze-thaw cycles. Some suppliers recommend brief centrifugation before opening the vial.
Store lyophilized peptide at -20 degrees C, protected from light and moisture. Reconstituted solutions should be aliquoted into single-use volumes and stored at -20 degrees C or -80 degrees C. Avoid repeated freeze-thaw cycles. Working solutions should be prepared fresh for each experiment when possible.
Tat-Beclin-1 dosing FAQ
How much bacteriostatic water should I add to a 5 mg vial of Tat-Beclin-1?
The community standard is 1 mL of bacteriostatic water for a 5 mg Tat-Beclin-1 vial. That gives a concentration of 2.50 mg/mL, so a 100 mcg dose is 4 units on a U-100 insulin syringe. Adding 1 mL instead doubles the concentration to 5.00 mg/mL and halves the draw to 2 units. Less water = smaller injection volume but harder to measure precisely.
How many syringe units is a 100 mcg dose of Tat-Beclin-1?
On a standard U-100 insulin syringe, a 100 mcg dose of Tat-Beclin-1 is 4 units when the 5 mg vial is reconstituted with 1 mL of bacteriostatic water (2.50 mg/mL). If you use 1 mL of bac water instead, draw 2 units (5.00 mg/mL).
What is the standard Tat-Beclin-1 dose?
Community-reported protocols for Tat-Beclin-1 typically use 100 mcg–200 mcg every other day via Subcutaneous. 100 mcg is a common starting dose. Extremely limited community data; doses extrapolated from in vitro concentrations and animal studies
How long does a vial of Tat-Beclin-1 last at 100 mcg every other day?
A 5 mg vial of Tat-Beclin-1 contains roughly 50 doses at 100 mcg per injection. At every other day dosing, that is approximately 100 days (about 14 weeks) of supply per vial. Reconstituted Tat-Beclin-1 should generally be used within 28 days when refrigerated.
Where do you inject Tat-Beclin-1?
Tat-Beclin-1 is typically administered subcutaneous. Common subcutaneous sites are the lower abdomen (at least an inch from the navel), the outer thigh, and the love handles. Rotate sites with each injection to reduce localized irritation and bruising.
Can I use sterile water instead of bacteriostatic water for Tat-Beclin-1?
Bacteriostatic water (containing 0.9% benzyl alcohol as a preservative) is strongly preferred for multi-dose vials like Tat-Beclin-1 because it inhibits microbial growth and lets a single vial be used over multiple weeks. Sterile water has no preservative and should generally be reserved for single-use preparations only.
More on Tat-Beclin-1
Tat-Beclin-1 overview
Mechanism of action, primary uses, and research summary
Tat-Beclin-1 dosing protocols
Full clinical and research-based dosing reference
Tat-Beclin-1 community protocols
Real-world usage patterns from peptide communities
Tat-Beclin-1 side effects
Reported adverse effects and safety considerations
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.